ライフサイエンスコーパス: postremission

1 tment cytogenetics in risk stratification of postremission AML therapy.

2 A comparison was made of 3 aggressive postremission approaches for children and adolescents wi

3 relapse rate or remission duration in either postremission arm.

4 The three postremission arms remain coded.

5 The most important component of the postremission chemotherapy continues to be several cours

6 imal dose, schedule, and number of cycles of postremission chemotherapy for most patients are not kno

7 conventional high-dose cytarabine (HDAC) as postremission chemotherapy in younger patients with acut

8 (64%) of 11 patients who received intensive postremission chemotherapy with high-dose cytarabine (at

9 ted timing of induction therapy and compared postremission chemotherapy with marrow transplantation i

10 Second, postremission chemotherapy with or without hematopoietic

11 ete remission (CR) relapse with conventional postremission chemotherapy.

12 Postremission consolidation chemotherapy with either pla

13 nia in patients with AML receiving intensive postremission consolidation with AZQ and mitoxantrone.

14 The data indicate that postremission consolidation with cytarabine before allog

15 ) at the time of diagnosis, (e) and a higher postremission cytarabine dose (P < 0.001).

16 detection of minimal residual disease at the postremission induction period by immunologic methods ar

17 The type of postremission intensification remained significant for D

18 Our results suggest that postremission interventions should be targeted toward pa

19 is higher-dose therapy had no benefit in the postremission management of older patients with de novo

20 DAC induction and consolidation had the best postremission outcomes; however, the proportion of CR pa

21 Among postremission patients, survival from CR varied signific

22 benefit to including this combination in the postremission phase of AML.

23 patients (18%) refused to participate in the postremission phase of this study.

24 superior long-term survival irrespective of postremission regimen received (allogeneic BMT, 70% +/-

25 These 2 postremission regimens produced similar outcomes.

26 ly diagnosed acute lymphoblastic leukemia to postremission regimens that included high-dose methotrex

27 of eight patients with t(9; 11) who received postremission regimens with cytarabine at a dose of 100

28 lopment of new therapeutic strategies in the postremission state.

29 Postremission stem cell transplantation should be consid

30 HCT) and prolonged chemotherapy are standard postremission strategies for adult acute lymphoblastic l

31 Various postremission strategies have been explored to eliminate

32 lenomegaly predicts a lower CR rate, and the postremission strategies of either four cycles of I/HDAC

33 y of response after chemotherapy and to plan postremission strategies that are, therefore, driven by

34 d treatments that could be incorporated into postremission strategies to improve survival for adults

35 bone marrow transplantation is an effective postremission strategy for patients with acute myelogeno

36 c markers in guiding chemotherapy choice and postremission strategy, as well as the utility of target

37 Postremission survival was 56% in patients randomized to

38 basis for prospective comparison with other postremission therapies considered standard in the manag

39 Postremission therapies with reduced toxicities are urge

40 re nuanced selection of patients for optimal postremission therapies.

41 ld in a clinical trial comparing 3 intensive postremission therapies: intensive chemotherapy, autolog

42 00 mg/m2 (2 patients) or who did not receive postremission therapy (2 patients) have relapsed.

43 ose cytarabine (HDAC) for both induction and postremission therapy for acute myeloid leukemia (AML) p

44 establish the role of vaccination as viable postremission therapy for acute myeloid leukemia.

45 The choice of either induction or postremission therapy for adults with acute myeloid leuk

46 The optimal postremission therapy for adults with ALL remains unclea

47 AlloSCT is the most potent postremission therapy for AML and is particularly active

48 e afforded by allogeneic BMT administered as postremission therapy for AML.

49 nisone was used as the corticosteroid during postremission therapy from 1987 to 1991, and dexamethaso

50 Patients who underwent allogeneic SCT as postremission therapy had longer survival than patients

51 as concurrent gene mutations, with regard to postremission therapy in 323 patients with FLT3-ITD-posi

52 Evaluate the outcome of induction and postremission therapy in adults younger than 60 years wi

53 risk stratification and might help to guide postremission therapy in NPM1-mutated AML.

54 Postremission therapy in patients with acute myeloid leu

55 lloHSCT) is considered the preferred type of postremission therapy in poor- and very-poor-risk AML, t

56 is now referred to you for consideration of postremission therapy in the setting of high-risk acute

57 After postremission therapy including intensive chemotherapy (

58 The optimal postremission therapy of acute myeloid leukemia (AML) in

59 mon HLA type) and presents for discussion of postremission therapy options.

60 Aggressive postremission therapy or the use of hematopoietic growth

61 erapy followed by 120 weeks of risk-assigned postremission therapy that included reinduction treatmen

62 atment, and the addition of dexamethasone to postremission therapy to increase the proportion of even

63 ceiving intensive timing irrespective of the postremission therapy to which they were allocated.

64 For the entire patient cohort, postremission therapy was an independent factor for OS (

65 This was followed by cyclical postremission therapy with high-dose cytarabine/etoposid

66 (16) and 49 adults with t(8;21), assigned to postremission therapy with repetitive cycles of higher d

67 erved to identify subgroups for risk-adapted postremission therapy, but the initial treatment approac

68 expanded use of arsenic trioxide in APL for postremission therapy, in conjunction with transplantati

69 Despite the use of postremission therapy, less than half of patients with A

70 tely, the currently available modalities for postremission therapy, namely chemotherapy, have proven

71 improve risk stratification and selection of postremission therapy.

72 atched to patients who received conventional postremission therapy.

73 nors may be considered for allogeneic SCT as postremission therapy.

74 cribe the implications for AML diagnosis and postremission therapy.

75 for t(9; 11) patients who receive intensive postremission therapy.

76 Despite an increased postremission toxic mortality (3 years: 6.6% v. 4.1%; Hz

77 Here, we review postremission transplantation strategies using either au

78 for the alloSCT and 46% for the conventional postremission treatment group (P = .037; log-rank test).

79 Postremission treatment was the same for all arms.

80 ved retinoic acid (RA) induction followed by postremission treatment with chemotherapy, RA, and biolo

81 All patients were randomly assigned to postremission treatment with standard-, intermediate-, o

82 romal recovery), and recurrence (new episode postremission) were also assessed.

83 During the postremission year, children of early-remitting mothers